Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 04; 19(6).

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Colitis, Ulcerative
Crohn Disease
Double-Blind Method
Female
Gastrointestinal Agents
Humans
Infliximab
Injections, Subcutaneous
Maintenance Chemotherapy
Male
Middle Aged
Treatment Outcome

authors with profiles

Stephen B. Hanauer